New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
08:20 EDTRDHLRedHill Biopharma announces FDA clearance for Phase III study with RHB-102
RedHill Biopharma announced that the FDA has allowed the initiation of the company's planned Phase III clinical study for the treatment of a new, undisclosed indication with RHB-102, an extended release oral pill formulation of the antiemetic drug ondansetron. RedHill plans to begin enrolling patients for the Phase III study during Q3. The double-blind placebo-controlled Phase III study is planned to be conducted in eight clinical sites in the U.S. and will include 320 subjects. Based on prior discussions with the FDA and the UK Medicines and Healthcare Products Regulatory Agency, or MHRA, the study is intended to support potential future submissions of marketing applications for a new undisclosed indication in both the U.S. and Europe. RedHill estimates that, if the Phase III clinical study is successful and the marketing applications are filed and approved by the FDA and the MHRA, the new indication would significantly expand the potential market for RHB-102. In parallel to pursuing the new undisclosed indication, RedHill is pursuing marketing approval of RHB-102 for the indications of chemotherapy and radiotherapy-induced nausea and vomiting in Europe and the U.S.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:09 EDTRDHLRedHill Biopharma receives notice of allowance for two U.S. patents for RHB-104
RedHill Biopharma announced that it has received two notices of allowance from the United States Patent and Trademark Office regarding its patent application numbers 13/722,395 and 14/271,758 covering RHB-104. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties, currently undergoing a first Phase III study for Crohn's disease and a Phase IIa study for multiple sclerosis.
June 29, 2015
07:08 EDTRDHLRedHill Biopharma initiates Phase I/II study of ABC294640
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use